Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Deals Digital Hospital

Zeiss Group and China’s Healthcare Cloud Collaborate on Ophthalmic Services in China

Fineline Cube Nov 15, 2023

Germany-based Zeiss Group, a leader in optical systems and optoelectronic product manufacturing, has entered into...

Company Drug

Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s

Fineline Cube Nov 15, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY)...

Company

CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments

Fineline Cube Nov 15, 2023

China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter...

Company Deals

Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal

Fineline Cube Nov 14, 2023

China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric...

Company Deals R&D

Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery

Fineline Cube Nov 14, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...

Company Deals

Autobio Diagnostics Expands Strategic Partnership with Guorun Medical Supply Chain Services

Fineline Cube Nov 14, 2023

China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with Guorun Medical...

Company Digital

BMS Secures ORM-6151 for Acute Myeloid Leukemia Treatment with Orum Therapeutics Deal

Fineline Cube Nov 14, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has made a significant move in the field of...

Company Drug

Bayer Withdraws Aliqopa FDA Filing Following Missed Phase III Endpoint

Fineline Cube Nov 14, 2023

Germany-based pharmaceutical major Bayer (ETR: BAYN) has announced its decision to withdraw the filing for...

Company Deals

Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics

Fineline Cube Nov 14, 2023

Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led...

Company Deals

AnchorDx Medical Partners with DiaCarta for Global Molecular Diagnostics Development

Fineline Cube Nov 14, 2023

AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing based in China, has entered...

Company

Sisram Medical Ltd Expands Asia-Pacific Presence with New Direct Sales Office in Japan

Fineline Cube Nov 14, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company that is part of the Fosun Pharmaceutical...

Company Deals

Beijing-Based Immupeutics Medicine Secures Tens of Millions in Pre-Series A+ Financing

Fineline Cube Nov 14, 2023

Immupeutics Medicine, a Beijing-based developer in the field of tumor immunotherapy, has reportedly secured tens...

Company Drug

Servier’s Tibsovo Receives FDA Approval for IDH1-Mutated R/R MDS, Expanding Indications

Fineline Cube Nov 14, 2023

France-based pharmaceutical company Servier has announced that the US Food and Drug Administration (FDA) has...

Company Drug

Huadong Medicine’s Arcalyst (Rilonacept) Filing for CAPSs Accepted by China’s NMPA

Fineline Cube Nov 14, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that the National...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ HR20031 Accepted for Review by China’s NMPA for Type 2 Diabetes

Fineline Cube Nov 14, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading Chinese pharmaceutical company, has announced that the National...

Company Drug

AstraZeneca’s Imfinzi Gains NMPA Approval for First-Line Cholangiocarcinoma Treatment

Fineline Cube Nov 14, 2023

The National Medical Products Administration (NMPA) of China has indicated on its website that it...

Company Drug

Hansoh Pharmaceutical’s HS-10511 Tablets for Hypertrophic Cardiomyopathy Cleared for Clinical Trials

Fineline Cube Nov 13, 2023

Hansoh Pharmaceutical (HKG: 3692) has announced that its affiliated company’s self-developed Class 1 new drug,...

Company Deals

Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE

Fineline Cube Nov 13, 2023

Among the series of deals secured by multinational corporations at the 6th China International Import...

Company Deals

Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology

Fineline Cube Nov 13, 2023

Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration...

Company Deals

Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent

Fineline Cube Nov 13, 2023

On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans...

Posts pagination

1 … 391 392 393 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.